Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A “real life” retrospective study on 175 patients - 06/01/09
Corresponding author. Tel.: +33 240 08 48 22 or 01; fax: +33 240 08 48 22 30.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
To assess in clinical practice the 6-month outcome in patients with axial spondylarthropathy (SpA) treated by anti-TNF, according to the fulfillment of New-York criteria (NY) for the diagnosis of ankylosing spondylitis (AS), or agreement with French recommendations (SFR) for anti-TNF use in SpA.
Methods |
Outcome could be retrospectively assessed according to the updated ASAS score (improvement of at least 50% or two units of the BASDAI) and the percentages of patients reaching at 6 month the patient BASDAI acceptable symptoms state (PASS) of 3.5.
Results |
A total of 175 out of 203 patients could be retrospectively assessed at 6 month. Fifty-eight percent fulfilled the NY criteria, and 81% satisfied SFR recommendations. After 6 months of anti-TNF treatment, patients with NY criteria (NY+) met the updated ASAS outcome more often than NY− (70% versus 58%) (chi-square: 0.041): reduction of BASDAI of 2.86±2.18 (NY+) versus 2.48±2.39 (NY−) (NS). PASS of 3.5 was reached in 64% (NY+) versus 49% (NY−). ASAS outcome was met in 45%/60%/69%/88% of patients with 0/1/2/≥3 parameters to guide physician's opinion from SFR: raised ESR or CRP was present in 66%, active enthesitis or arthritis in 49%, coxitis in 13%, active or relapsing uveitis in 11%, inflammation of sacro–iliac or spine on MRI in 12%, and worsening of articular damage in 5%.
Conclusion |
The effectiveness of TNF-blockers was slightly better in patients fulfilling the NY criteria for AS or SFR recommendations, but 58% of axial SpA not fulfilling NY criteria, and 48% of patients not satisfying French recommendations also met ASAS outcome.
Le texte complet de cet article est disponible en PDF.Keywords : Axial, Spondylarthropathy, Ankylosing spondylitis, Anti-TNF, ASAS, Guidelines, Outcome, PASS, Undifferentiated, BASDAI
Plan
Vol 75 - N° 6
P. 680-687 - décembre 2008 Retour au numéro
Article précédent
- Osteoarthritis and obesity: Experimental models
- Odile Gabay, David J. Hall, Francis Berenbaum, Yves Henrotin, Christelle Sanchez
- Budget impact model of rituximab after failure of one or more TNF
inhibitor therapies in the treatment of rheumatoid arthritis - Robert Launois, Stéphanie Payet, Nathalie Saidenberg-Kermanac'h, Camille Francesconi, Lionel Riou França, Marie-Christophe Boissier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?